Contract Research Expenses (65% Rule)

Under the Pennsylvania Research and Development Tax Credit, contract research expenses represent sixty-five percent of the total amount paid to third-party entities for qualified research activities conducted within the Commonwealth. This statutory limitation is designed to isolate the direct costs of technical innovation by excluding the contractor’s overhead and profit margins from the qualified expense base.

The regulatory environment surrounding the Pennsylvania Research and Development (R&D) Tax Credit is a complex intersection of state statutory law, federal definitions, and administrative guidance issued by the Pennsylvania Department of Revenue. Codified under Article XVII-B of the Tax Reform Code of 1971, the program serves as a cornerstone of the Commonwealth’s economic development strategy, aiming to incentivize long-term investment in scientific discovery and technological advancement. The “65% Rule” specifically addresses the treatment of expenditures incurred when a taxpayer engages external expertise—such as engineering firms, independent laboratories, or software developers—to perform research on their behalf. To navigate this framework, professional practitioners must look beyond the simple percentage and understand the rigorous requirements regarding geographic nexus, economic risk, and substantial rights, all of which determine whether an external payment qualifies for the credit.

Legislative Architecture and the Evolution of Article XVII-B

The Pennsylvania Research and Development Tax Credit was formally established by Act 7 of 1997, which introduced Article XVII-B into the Tax Reform Code of 1971. The primary objective of this legislation was to foster an environment conducive to high-tech growth by allowing businesses to offset their state tax liabilities based on incremental increases in research spending. Since its inception, the program has undergone significant legislative modifications to improve its accessibility and impact. Act 46 of 2003 was a pivotal update, as it introduced the ability for taxpayers to sell or assign unused credits, providing much-needed liquidity to pre-revenue startups. This update also removed the original 50% limitation on tax liability offset, allowing credits to reduce up to 100% of a taxpayer’s qualified tax liability for tax years beginning after 2004.

More recently, the program has been reinforced through Act 25 of 2021 and Act 53 of 2022. Act 25 modernized the administrative timeline, shifting the application deadline from September 15 to December 1 and establishing a formal appeals process for taxpayers who disagree with the Department’s credit determinations. Act 53 of 2022 increased the annual statewide cap on credit awards from $55 million to $60 million, with a specific $12 million set-aside to protect the interests of qualified small businesses. These legislative shifts indicate a consistent commitment by the Commonwealth to support innovation, even as broader economic conditions fluctuate.

Legislative Act	Key Provision	Impact on R&D Tax Credit
Act 7 of 1997	Introduction of Article XVII-B	Established the state-level R&D tax credit and the 65% rule.
Act 46 of 2003	Transferability and Offset	Allowed the sale of unused credits and enabled 100% tax liability offset.
Act 43 of 2017	Tax Clearance Requirement	Mandated compliance with all state taxes as a prerequisite for awards.
Act 25 of 2021	Deadline and Appeals	Shifted application to Dec 1 and created an administrative appeals process.
Act 53 of 2022	Cap Increase	Raised total pool to $60 million and small business set-aside to $12 million.

Definitional Standards and the 65% Rule Mechanism

The definition of “Pennsylvania qualified research and development expense” (PQRE) is the fundamental starting point for any credit calculation. Section 1702-B of the Tax Reform Code defines these expenses by direct reference to Section 41(b) of the Internal Revenue Code (IRC), though with a strict requirement that the research must be conducted within Pennsylvania. Under this framework, contract research expenses are treated as a distinct category of expenditure, separate from in-house wages and supplies.

The Conceptual Foundation of the 65% Haircut

The 65% rule functions as a statutory “haircut” applied to the total amount paid by a taxpayer to any person, other than an employee, for the performance of qualified research. This reduction reflects a policy assumption that a portion of any third-party invoice includes non-research costs such as the contractor’s profit, general administrative overhead, and facility costs. By limiting the inclusion to 65%, the law attempts to approximate the actual direct labor and materials the contractor devoted to the project.

This distinction is critical for taxpayers who must choose between expanding an internal research team or outsourcing specific technical challenges. While 100% of internal wages for qualified services are eligible for the credit, only 65% of the external equivalent is recognized. This delta requires careful financial planning, particularly for companies that rely heavily on specialized testing laboratories or engineering consultants to validate their innovations.

Distinguishing Between Contractors and Employees

The application of the 65% rule hinges on the classification of the individual performing the work. Under Pennsylvania law and the IRC, “employees” are those whose wages are subject to withholding and reported on a Form W-2. Payments to these individuals for qualified services are included at 100%. Conversely, any person or entity engaged under a 1099-Misc or a corporate contract is deemed a third-party contractor, and payments to them are subject to the 65% limitation.

The Department of Revenue maintains a strict stance on this classification, warning applicants that improperly including third-party expenditures as “direct wages” is a common error that can lead to the denial of the entire application. Accurate record-keeping must distinguish between these two pools of capital from the inception of the research project.

The Geographic Nexus and Pennsylvania Requirement

A defining characteristic of the Pennsylvania R&D Tax Credit is its uncompromising geographic requirement. While the federal R&D credit applies to research performed anywhere within the United States, the Pennsylvania credit is exclusively for research conducted within the borders of the Commonwealth.

The Physical Location of Research Activities

For a contract research expense to qualify for the 65% rule, the contractor must physically perform the research within Pennsylvania. The location of the taxpayer’s headquarters is irrelevant if the work is performed elsewhere. If a Pittsburgh-based robotics firm hires a software contractor in India or even in neighboring New Jersey, those expenses are entirely disqualified from the Pennsylvania credit, regardless of their eligibility for the federal credit.

This creates a significant administrative burden for taxpayers who engage contractors with multiple offices or a remote workforce. In such instances, the taxpayer must obtain documentation from the contractor specifying the exact location where the qualified services were rendered. The Department of Revenue’s myPATH application portal requires the project address to be provided for each claimed expenditure, reinforcing this territorial nexus.

Apportionment and Multi-State Contracts

In scenarios where a single contract covers research activities performed both inside and outside the Commonwealth, the taxpayer must apportion the costs. Only the 65% of the portion of the contract price attributable to Pennsylvania-based activities can be included in the PQRE calculation. For example, if an engineering firm is paid $100,000 for a project where 40% of the man-hours were spent at a lab in Philadelphia and 60% at a lab in Delaware, only $40,000 is eligible for the state credit calculation, resulting in a PQRE of $26,000 ($40,000 x 0.65).

Contractual Integrity: The Economic Risk and Substantial Rights Tests

The eligibility of contract research expenses is further governed by the “Economic Risk” and “Substantial Rights” tests, which are derived from Treasury Regulation § 1.41-2(e) and adopted by Pennsylvania. These tests are designed to ensure that the party claiming the credit is the one truly bearing the burden and uncertainty of the innovation.

The Doctrine of Economic Risk

For an expense to be qualified, the taxpayer must be “at risk” for the research. This means that the taxpayer must be obligated to pay for the research even if it fails to produce the desired result.

• Time and Materials Contracts: These are generally favorable for credit eligibility because the taxpayer pays for the contractor’s hours regardless of the outcome.
• Fixed-Price Success-Based Contracts: These are often problematic. If a contract stipulates that the taxpayer only pays if the contractor delivers a functional prototype, the contractor is the one bearing the economic risk of failure. In such cases, the research may be considered “funded,” and the hiring party cannot claim the 65% contract research expense.

Retention of Substantial Rights

The second prong of the test requires that the taxpayer retain “substantial rights” to the research results. While these rights do not have to be exclusive, the taxpayer must be able to use the research results in their own trade or business without paying a royalty or licensing fee to the contractor. If a contractor retains all intellectual property and the taxpayer is merely purchasing a license for a finished product, the 65% rule does not apply because the taxpayer is purchasing an asset rather than engaging in research.

Test Prong	Requirement for Taxpayer	Evidence Needed
Economic Risk	Payment must be required regardless of success/failure.	Contracts showing no contingency on results; evidence of payment for failed trials.
Substantial Rights	Taxpayer must have right to use IP without additional fees.	IP ownership clauses; non-exclusive perpetual license language in the agreement.

Specialized Inclusion Rates: Consortia and Basic Research

While the 65% rule is the standard for most commercial contracts, Pennsylvania law recognizes higher inclusion rates for collaborative research involving non-profit and academic institutions.

The 75% Consortium Rule

If a taxpayer pays a “qualified research consortium” to perform research, 75% of those expenses may be included in the PQRE base. A qualified research consortium is defined as a tax-exempt organization (under IRC Section 501(c)(3) or 501(c)(6)) that is operated primarily to conduct scientific research and is not a private foundation. This higher rate incentivizes businesses to participate in industry-wide research initiatives that have broader economic and scientific benefits.

Basic Research Payments to Universities

Payments made to qualified organizations, such as Pennsylvania colleges or universities, for “basic research” are subject to specialized calculation rules. Basic research is defined as any original investigation for the advancement of scientific knowledge that does not have a specific commercial objective.

• The Tax Reform Code specifies that the portion of basic research payments that does not exceed a “qualified organization base period amount” is treated as contract research expense (subject to the 65% rule).
• Amounts exceeding this base period amount are treated as a separate basic research credit component, often providing a higher effective benefit.

This tiered approach ensures that while all external research is incentivized, the Commonwealth places a higher premium on foundational scientific inquiry performed within its academic ecosystem.

Administrative Guidance from the Department of Revenue

The Pennsylvania Department of Revenue provides the operative guidance for claiming these credits through the myPATH portal and the instructions for Form REV-545. Compliance with these procedures is mandatory, as the Department performs rigorous tax clearances on all applicants.

The myPATH Application Workflow

Taxpayers must submit their applications by December 1 following the close of the tax year in which the expenses were incurred. The online application requires detailed technical and financial data for each project.

1. Project Description: For every project involving contract research, the taxpayer must provide a narrative explaining how the project meets the Four-Part Test: Elimination of Uncertainty, Process of Experimentation, Technological in Nature, and Qualified Purpose.
2. Subcontractor Disclosure: The taxpayer must list every contractor paid for R&D services, including their Name, FEIN, address, and the total amount paid.
3. Federal Alignment: Applicants are required to attach a copy of their as-filed Federal Form 6765. The 65% contract research figures reported on the Pennsylvania application should be reconcilable with the figures reported on the federal form, adjusted for geographic location.

Common Pitfalls and Documentation Errors

The Department of Revenue emphasizes that “General Questions” or hypothetical scenarios are not sufficient for private letter rulings; they require specific, fact-based inquiries. In the absence of a ruling, taxpayers must avoid common filing errors:

• Failure to Provide FEINs: Missing FEINs for subcontractors will cause the application to be rejected during the automated validation process.
• Inadequate Narrative Detail: Using marketing language instead of technical engineering descriptions can result in the disqualification of the project’s expenses.
• Address Abbreviations: The myPATH system is sensitive to address formatting; abbreviations should be avoided to ensure successful processing.

Calculation Dynamics and the Incremental Nature of the Credit

The Pennsylvania R&D tax credit is not a flat percentage of spending; it is an incremental credit that rewards companies for increasing their research investments over time.

The Pennsylvania Base Amount

The “Pennsylvania base amount” is the benchmark against which current-year spending is measured. It is generally the average of the taxpayer’s PQREs for the four taxable years immediately preceding the credit year.

• The 50% Rule: By statute, the base amount can never be less than 50% of the current year’s qualified research expenses. This floor ensures that the credit is only awarded for significant spending, but it also limits the benefit for companies that are rapidly scaling their R&D operations.

Calculation Example for Large vs. Small Business

The credit rate depends on the size of the entity. Small businesses (assets < $5 million) receive a 20% rate on the excess, while larger businesses receive a 10% rate.

Metric	Large Business (Example)	Small Business (Example)
Current Year PQRE	$1,000,000	$1,000,000
Base Amount (Avg. Prior 4 Yrs)	$600,000	$600,000
Eligible Excess	$400,000	$400,000
Credit Rate	10%	20%
Tentative Credit	$40,000	$80,000

This tiered structure reflects a policy goal of providing greater proportional support to smaller, more capital-constrained innovators who may be more reliant on external contractors due to a lack of in-house laboratory facilities.

Proration and the Statewide Program Cap

A critical, and often frustrating, aspect of the Pennsylvania program is the annual cap and the resulting proration of awards. The program is currently capped at $60 million per year.

Oversubscription and Proration Factors

Because the demand for the credit typically exceeds the $60 million supply, the Department of Revenue must prorate the tentative credits calculated on applications.

• Small Business Set-Aside: $12 million is reserved exclusively for small businesses. If small business requests total less than $12 million, they may receive 100% of their tentative credit.
• Large Business Proration: The remaining $48 million is distributed among all other qualified applicants. This frequently leads to significant proration. For instance, in 2024, “not small” businesses received only 41.1% of their tentative requested credits.

This mechanism means that a large company that calculates a $1,000,000 tentative credit based on its 65% contract research expenses may actually only receive a credit award of $411,000. Taxpayers must account for this variability when forecasting the net tax benefit of their R&D activities.

Transferability and the Secondary Market for Credits

Pennsylvania is one of the few states that allows R&D tax credits to be sold or assigned to other taxpayers. This creates a secondary market where companies can monetize their innovation incentives even if they have no current tax liability.

Mechanics of the Sale

The sale of a credit is a multi-step process involving both the Department of Revenue and the Department of Community and Economic Development (DCED).

• Hold Period: Historically, there was a one-year holding period before a credit could be sold. Act 46 of 2003 allowed for immediate sale upon approval for credits awarded in 2009 and later.
• Sale Value: Credits typically sell at a discount, often ranging from 90 to 95 cents on the dollar. In 2024, the historical retention value of sold credits was reported at 92.9%.
• Buyer Restrictions: The purchaser of a credit can use it to offset up to 75% of their tax liability in the year of purchase. The buyer cannot carry the credit forward or resell it; it is a “use it or lose it” asset for the purchaser.

This transferability is particularly valuable for the life sciences and software sectors, where high R&D spending often precedes profitability by several years.

Comprehensive Practical Example: MedTech Innovations Corp

To synthesize these rules, consider MedTech Innovations Corp, a medical device startup based in Erie, Pennsylvania. MedTech is developing a new robotic surgical arm and lacks the internal capability to perform advanced material stress testing.

The Research Project

In 2024, MedTech engaged a specialized testing laboratory in Pittsburgh (the “Contractor”) to perform stress tests on the robotic arm’s alloy joints.

• Contract Terms: MedTech agreed to pay the Contractor $300,000. The contract stipulated that MedTech would pay for the hours worked even if the joints failed the test (Economic Risk). Furthermore, the contract stated that all data and intellectual property resulting from the tests would be owned by MedTech (Substantial Rights).
• Location: All testing was performed at the Contractor’s laboratory in Pittsburgh (Geographic Nexus).
• Business Profile: MedTech has total assets of $3.5 million, qualifying it as a Pennsylvania small business.

Calculation of PQRE

First, MedTech applies the 65% Rule to the contract payment:

$300,000 x 0.65 = $195,000

This $195,000 is the amount of PQRE attributable to the contract research.

Determination of the Credit

Assume MedTech’s Pennsylvania base amount (prior 4-year average) is $100,000.

1. Current Year PQRE: $195,000
2. Base Amount: $100,000 (Note: $100,000 is greater than the 50% minimum of $97,500, so it stands).
3. Qualified Increase: $195,000 – $100,000 = $95,000.
4. Credit Rate: As a small business, MedTech receives 20%.
5. Tentative Credit: $95,000 x 0.20 = $19,000.

Award and Monetization

MedTech applies via myPATH by December 1, providing the Contractor’s FEIN and a technical narrative of the stress testing process. In May of the following year, the Department approves the $19,000 credit. Because MedTech is in a loss position and has no tax liability, it decides to sell the credit. It finds a buyer (a large Pennsylvania manufacturing firm) that purchases the credit for 92 cents on the dollar. MedTech receives $17,480 in cash to reinvest in its next phase of development.

Compliance and Future Outlook for 2025 and Beyond

The regulatory landscape for R&D tax credits is currently undergoing significant changes at both the federal and state levels. The Tax Cuts and Jobs Act (TCJA) introduced a requirement that businesses amortize R&D expenses over five years rather than deducting them immediately. While this is a federal income tax provision, it impacts the calculation of the credit because it changes the underlying tax reporting on which state applications are based.

Legislative Trends in 2025

Recent commentary indicates that starting in 2025, new legislation (referred to as the “One Big Beautiful Bill”) may restore immediate expensing for domestic R&D costs. For Pennsylvania taxpayers, this would simplify the alignment between state and federal documentation and likely increase the volume of R&D investment within the Commonwealth. Additionally, for small businesses with gross receipts under $31 million, new rules may allow for retroactive refunds of capitalized costs from 2022 to 2024, providing a significant cash infusion to the tech sector.

Sustaining Audit Readiness

As the credit cap remains a point of legislative debate, the Department of Revenue’s scrutiny of applications is expected to intensify. Taxpayers must maintain contemporaneous documentation that links every contractor invoice to a specific technological uncertainty being solved. This documentation should include:

• Project-level time tracking for contractors (if available).
• Detailed statements of work (SOWs) that highlight technical challenges.
• Correspondence with contractors discussing failed tests or design iterations.
• Final technical reports proving the “Process of Experimentation” occurred.

The Pennsylvania Research and Development Tax Credit remains a vital, albeit complex, incentive for firms operating at the edge of technological possibility. By understanding the 65% rule not just as a mathematical constant, but as a gateway to broader compliance and strategic tax planning, businesses can effectively leverage external expertise to fuel their internal growth within the Commonwealth. Success in this domain requires a holistic view that integrates legal contract review, precise accounting, and rigorous technical documentation to satisfy the Department of Revenue’s exacting standards.

Final Thoughts

The information above provides a detailed look at the 65% rule. Ensuring compliance with these guidelines is essential for maximizing your R&D tax credit potential in Pennsylvania.